The biotechnology sector is currently at a strategic crossroads, marked by disruptive technological innovations and major economic challenges. The "patent cliff," representing a potential loss of $400 billion, is pushing companies to innovate rapidly to compensate for the loss of patents. Artificial intelligence (AI) is at the heart of this transformation, facilitating drug discovery and optimizing research and development (R&D) processes. Recent fundraisings and strategic partnerships demonstrate the growing interest in AI within this sector.